North America Insulin Market- Analysis and Forecast (2017 - 2022)

In 2012, 29.1 million Americans, or 9.3% of the population, had diabetes. Of the 29.1 million, 21.0 million were diagnosed, and 8.1 million were undiagnosed. In 2010 the figures were 25.8 million with 18.8 million diagnosed cases and 7.0 million undiagnosed cases. Likewise in Canada 6.4% of the total population suffer from diabetics and these numbers are set to rise by 42% by the year 2030. Since its introduction in1982 into the US market by Eli Lilly the human insulin market has gradually expanded into all of North America.

Since its introduction Insulin has been majorly administered via the Syringe and needle, but developments in the insulin delivery market has increased the acceptance of human insulin and has improving patient convenience and enhanced glycemic control.

The launch of insulin pen injectors in 1985 by Novo Nordisk established a template in diabetes treatment, but the introduction and developments in the diabetic pump delivery systems is what has been driving the insulin market in North America especially in the USA. An estimated 400,000 people use insulin pumps in the US.

Recent surveys have shown 20 % of Us Type 1 diabetics patients use insulin pumps , far more than in any European country.

1. Introduction

2. Market Definition

3. Market Drivers

4. Market Restraints

5. North American Therapuetic Insulin

5.1 Overview

5.2 Innovations in insulin

5.3 Global Insulin market

5.4 Segmentation By Mode of action

5.4.1 Fast Acting Insulin analog

5.4.2 Slow Acting (basal) insulin analog

5.4.3 Long-acting injected insulin

5.5 Segmentation By Delivery Techology

5.5.1 Syringes

5.5.2 Pens

5.5.3 Pumps

5.5.4 Inhalers

5.5.5 Pills

6. Regional Insulin Market ( Market size, Forecast and CAGR)

6.1 North American Market for Insulin ( Market size, Forecast and CAGR)

6.2 Overivew

6.2.1 USA

6.2.2 Canada

6.2.3 Mexico

7. Competitive Landscape

8. Future Of the Insulin Market

9. Key Players in the Market

9.1 Eli Lily

9.2 Novo Nordisk

9.3 Sanofi Aventis

10. Biosimilar Insulin Market and Key players

10.1 Boehringer Ingelheim

10.2 Eli Lilly

11. Appendiix

Content are not available

Choose License Type